Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting-Reference-Cited by-同舟云学术

Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

Published:2024-02 Issue: Volume:51 Page:101332
ISSN:2352-5789
Container-title:Gynecologic Oncology Reports
language:en
Short-container-title:Gynecologic Oncology Reports

Author:

Rimel Bobbie J.,Chase Dana M.,Perhanidis Jessica,Ghazarian Armen A.,Du Ella Xiaoyan,Wang Travis,Song Jinlin,Golembesky Amanda K.,Hurteau Jean A.,Kalilani Linda,Salani Ritu,Monk Bradley J.

Funder

GlaxoSmithKline

Publisher

Elsevier BV

Reference16 articles.

1. AstraZeneca, 2019. LYNPARZA® (olaparib) tablets, for oral use: Highlights of prescribing information. 2019 [cited 2023 May 19, 2023]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s009lbl.pdf.

2. Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?;DiSilvestro;Cancers (Basel),2021

3. Clovis Oncology Inc, 2022. RUBRACA® (rucaparib) tablets, for oral use: Highlights of prescribing information. [cited 2023 May 19, 2023]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf.

4. EMA, 2012. Guideline on the investigation of drug interactions. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf.

5. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer;Friedlander;Asia Pac. J. Clin. Oncol.,2016